Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more
Kainos Medicine Inc (284620) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.551x
Based on the latest financial reports, Kainos Medicine Inc (284620) has a cash flow conversion efficiency ratio of -0.551x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion) by net assets (₩5.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kainos Medicine Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Kainos Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kainos Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kainos Medicine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Southern Energy Corp
V:SOU
|
0.062x |
|
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
|
-0.336x |
|
Generic Sweden publ AB
ST:GENI
|
0.190x |
|
Allbirds Inc
NASDAQ:BIRD
|
-0.293x |
|
PharmaSGP Holding SE
F:PSG
|
0.115x |
|
HeraMED Limited
F:1I4
|
-0.309x |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
0.284x |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
0.010x |
Annual Cash Flow Conversion Efficiency for Kainos Medicine Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Kainos Medicine Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.79 Billion | ₩-9.71 Billion | -5.430x | -348.73% |
| 2023-12-31 | ₩11.75 Billion | ₩-14.22 Billion | -1.210x | -179.71% |
| 2022-12-31 | ₩26.11 Billion | ₩-11.30 Billion | -0.433x | +43.05% |
| 2021-12-31 | ₩12.10 Billion | ₩-9.20 Billion | -0.760x | -23.35% |
| 2020-12-31 | ₩12.35 Billion | ₩-7.61 Billion | -0.616x | -3385.22% |
| 2019-12-31 | ₩9.91 Billion | ₩185.74 Million | 0.019x | +937.07% |
| 2018-12-31 | ₩9.83 Billion | ₩-22.01 Million | -0.002x | +92.18% |
| 2017-12-31 | ₩950.59 Million | ₩-27.23 Million | -0.029x | -- |